Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial

Ronald Chow; Keyue Ding; Vithusha Ganesh; Ralph M. Meyer; Yvette M. van der Linden; Daniel Roos; William F. Hartsell; Peter Hoskin; Jackson S. Y. Wu; Abdenour Nabid; Manouk van Acht; Rinus Wanders; Scott Babington; William F. Demas; Carolyn F. Wilson; Rebecca K. S. Wong; Michael Brundage; Liting Zhu; Edward Chow

doi:10.1016/j.radonc.2017.10.006

Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial

Ronald Chow, Keyue Ding, Vithusha Ganesh, Ralph M. Meyer, Yvette M. van der Linden, Daniel Roos, William F. Hartsell, Peter Hoskin, Jackson S. Y. Wu, Abdenour Nabid, Manouk van Acht, Rinus Wanders, Scott Babington, William F. Demas, Carolyn F. Wilson, Rebecca K. S. Wong, Michael Brundage, Liting Zhu, Edward Chow^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background and purpose: Patient's gender and age may influence physicians in prescribing palliative radiotherapy. The purpose of this secondary analysis of the National Cancer Institute of Canada Clinical Trials Group Symptom Control Trial SC.20 was to explore the gender and age differences in pain and patient reported outcomes in cancer patients with bone metastases undergoing re-irradiation.

Materials and methods: Response to radiation was evaluated using the International Bone Metastases Consensus Endpoint Definitions. Patients completed the Brief Pain Inventory (BPI) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (00) before and 2 months after re-irradiation.

Results: A total of 847 patients were analyzed. At baseline, men had more dyspnea, and mild pain. Older patients consumed less analgesic. More women reported clinically significant improvement in mood and enjoyment of life in the BPI after radiation. Similarly, younger patients reported better improvement in enjoyment of life. There were no significant gender or age differences in overall survival, response to radiation, or in 00 scores at 2 months.

Conclusion: Similar benefit in terms of pain relief was observed across all patient groups. Cancer patients with bone metastases should be offered palliative re-irradiation irrespective of gender or age. Trial Registration: NCT00080912; https://clinicaltrials.gov/ct2/show/NCT00080912. (C) 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 126 (2018) 541-546

Original language	English
Pages (from-to)	541-546
Number of pages	6
Journal	Radiotherapy and Oncology
Volume	126
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2017.10.006
Publication status	Published - Mar 2018

Keywords

Gender
Age
Bone metastases
Radiotherapy
Pain response
Quality of life
Re-irradiation
QUALITY-OF-LIFE
PALLIATIVE RADIOTHERAPY
CANCER PAIN
SEX-DIFFERENCES
CLINICAL-TRIALS
RADIATION-THERAPY
UNITED-STATES
MANAGEMENT
CONSENSUS
BARRIERS

Access to Document

10.1016/j.radonc.2017.10.006

Cite this

Chow, R., Ding, K., Ganesh, V., Meyer, R. M., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S. Y., Nabid, A., van Acht, M., Wanders, R., Babington, S., Demas, W. F., Wilson, C. F., Wong, R. K. S., Brundage, M., Zhu, L., & Chow, E. (2018). Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial. Radiotherapy and Oncology, 126(3), 541-546. https://doi.org/10.1016/j.radonc.2017.10.006

@article{74060049564243a2ae006a4cccf17308,

title = "Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial",

abstract = "Background and purpose: Patient's gender and age may influence physicians in prescribing palliative radiotherapy. The purpose of this secondary analysis of the National Cancer Institute of Canada Clinical Trials Group Symptom Control Trial SC.20 was to explore the gender and age differences in pain and patient reported outcomes in cancer patients with bone metastases undergoing re-irradiation.Materials and methods: Response to radiation was evaluated using the International Bone Metastases Consensus Endpoint Definitions. Patients completed the Brief Pain Inventory (BPI) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (00) before and 2 months after re-irradiation.Results: A total of 847 patients were analyzed. At baseline, men had more dyspnea, and mild pain. Older patients consumed less analgesic. More women reported clinically significant improvement in mood and enjoyment of life in the BPI after radiation. Similarly, younger patients reported better improvement in enjoyment of life. There were no significant gender or age differences in overall survival, response to radiation, or in 00 scores at 2 months.Conclusion: Similar benefit in terms of pain relief was observed across all patient groups. Cancer patients with bone metastases should be offered palliative re-irradiation irrespective of gender or age. Trial Registration: NCT00080912; https://clinicaltrials.gov/ct2/show/NCT00080912. (C) 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 126 (2018) 541-546",

keywords = "Gender, Age, Bone metastases, Radiotherapy, Pain response, Quality of life, Re-irradiation, QUALITY-OF-LIFE, PALLIATIVE RADIOTHERAPY, CANCER PAIN, SEX-DIFFERENCES, CLINICAL-TRIALS, RADIATION-THERAPY, UNITED-STATES, MANAGEMENT, CONSENSUS, BARRIERS",

author = "Ronald Chow and Keyue Ding and Vithusha Ganesh and Meyer, {Ralph M.} and {van der Linden}, {Yvette M.} and Daniel Roos and Hartsell, {William F.} and Peter Hoskin and Wu, {Jackson S. Y.} and Abdenour Nabid and {van Acht}, Manouk and Rinus Wanders and Scott Babington and Demas, {William F.} and Wilson, {Carolyn F.} and Wong, {Rebecca K. S.} and Michael Brundage and Liting Zhu and Edward Chow",

year = "2018",

month = mar,

doi = "10.1016/j.radonc.2017.10.006",

language = "English",

volume = "126",

pages = "541--546",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

Chow, R, Ding, K, Ganesh, V, Meyer, RM, van der Linden, YM, Roos, D, Hartsell, WF, Hoskin, P, Wu, JSY, Nabid, A, van Acht, M, Wanders, R, Babington, S, Demas, WF, Wilson, CF, Wong, RKS, Brundage, M, Zhu, L & Chow, E 2018, 'Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial', Radiotherapy and Oncology, vol. 126, no. 3, pp. 541-546. https://doi.org/10.1016/j.radonc.2017.10.006

TY - JOUR

T1 - Gender and age make no difference in the re-irradiation of painful bone metastases

T2 - A secondary analysis of the NCIC CTG SC.20 randomized trial

AU - Chow, Ronald

AU - Ding, Keyue

AU - Ganesh, Vithusha

AU - Meyer, Ralph M.

AU - van der Linden, Yvette M.

AU - Roos, Daniel

AU - Hartsell, William F.

AU - Hoskin, Peter

AU - Wu, Jackson S. Y.

AU - Nabid, Abdenour

AU - van Acht, Manouk

AU - Wanders, Rinus

AU - Babington, Scott

AU - Demas, William F.

AU - Wilson, Carolyn F.

AU - Wong, Rebecca K. S.

AU - Brundage, Michael

AU - Zhu, Liting

AU - Chow, Edward

PY - 2018/3

Y1 - 2018/3

N2 - Background and purpose: Patient's gender and age may influence physicians in prescribing palliative radiotherapy. The purpose of this secondary analysis of the National Cancer Institute of Canada Clinical Trials Group Symptom Control Trial SC.20 was to explore the gender and age differences in pain and patient reported outcomes in cancer patients with bone metastases undergoing re-irradiation.Materials and methods: Response to radiation was evaluated using the International Bone Metastases Consensus Endpoint Definitions. Patients completed the Brief Pain Inventory (BPI) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (00) before and 2 months after re-irradiation.Results: A total of 847 patients were analyzed. At baseline, men had more dyspnea, and mild pain. Older patients consumed less analgesic. More women reported clinically significant improvement in mood and enjoyment of life in the BPI after radiation. Similarly, younger patients reported better improvement in enjoyment of life. There were no significant gender or age differences in overall survival, response to radiation, or in 00 scores at 2 months.Conclusion: Similar benefit in terms of pain relief was observed across all patient groups. Cancer patients with bone metastases should be offered palliative re-irradiation irrespective of gender or age. Trial Registration: NCT00080912; https://clinicaltrials.gov/ct2/show/NCT00080912. (C) 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 126 (2018) 541-546

AB - Background and purpose: Patient's gender and age may influence physicians in prescribing palliative radiotherapy. The purpose of this secondary analysis of the National Cancer Institute of Canada Clinical Trials Group Symptom Control Trial SC.20 was to explore the gender and age differences in pain and patient reported outcomes in cancer patients with bone metastases undergoing re-irradiation.Materials and methods: Response to radiation was evaluated using the International Bone Metastases Consensus Endpoint Definitions. Patients completed the Brief Pain Inventory (BPI) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (00) before and 2 months after re-irradiation.Results: A total of 847 patients were analyzed. At baseline, men had more dyspnea, and mild pain. Older patients consumed less analgesic. More women reported clinically significant improvement in mood and enjoyment of life in the BPI after radiation. Similarly, younger patients reported better improvement in enjoyment of life. There were no significant gender or age differences in overall survival, response to radiation, or in 00 scores at 2 months.Conclusion: Similar benefit in terms of pain relief was observed across all patient groups. Cancer patients with bone metastases should be offered palliative re-irradiation irrespective of gender or age. Trial Registration: NCT00080912; https://clinicaltrials.gov/ct2/show/NCT00080912. (C) 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 126 (2018) 541-546

KW - Gender

KW - Age

KW - Bone metastases

KW - Radiotherapy

KW - Pain response

KW - Quality of life

KW - Re-irradiation

KW - QUALITY-OF-LIFE

KW - PALLIATIVE RADIOTHERAPY

KW - CANCER PAIN

KW - SEX-DIFFERENCES

KW - CLINICAL-TRIALS

KW - RADIATION-THERAPY

KW - UNITED-STATES

KW - MANAGEMENT

KW - CONSENSUS

KW - BARRIERS

U2 - 10.1016/j.radonc.2017.10.006

DO - 10.1016/j.radonc.2017.10.006

M3 - Article

C2 - 29102263

SN - 0167-8140

VL - 126

SP - 541

EP - 546

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -